secwatch.observer — SEC 8-K summary
======================================

Issuer:     Perspective Therapeutics, Inc. (CATX)
CIK:        0000728387
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0000950170-25-059557
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Perspective Therapeutics doses first patient in Phase 1/2a trial of PSV359 for FAP-α positive solid tumors
--------------------------------------------------------------------------------

- First patient dosed with [212Pb]PSV359 in Phase 1/2a dose-finding trial for FAP-α positive solid tumors.
- Patients selected via SPECT imaging with [203Pb]PSV359 to identify FAP-α expression.
- Trial aims to determine safety and preliminary anti-tumor activity; dose selection for monotherapy or combination.
- PSV359 construct optimized for tumor uptake, retention, and fast clearance from healthy tissues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/728387/000095017025059557/0000950170-25-059557-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/728387/000095017025059557/catx-20250429.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-059557

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer